Difference between revisions of "Adebrelimab (SHR-1316)"
Jump to navigation
Jump to search
(Created page with "Category:Drugs Category:Intravenous medications Category:T-cell activators Category:Anti-PD-L1 antibodies Category:Small cell lung cancer medications (inv...") |
m |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| + | ==Mechanism of action== | ||
| + | *From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adebrelimab NCI Drug Dictionary]: An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. | ||
| + | ==Also known as== | ||
| + | *'''Code names:''' HTI-1088, SHR-1316 | ||
| + | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| Line 8: | Line 13: | ||
[[Category:Small cell lung cancer medications (investigational)]] | [[Category:Small cell lung cancer medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
| + | |||
| + | [[Category:Stub]] | ||
Latest revision as of 23:45, 31 July 2023
Mechanism of action
- From the NCI Drug Dictionary: An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells.
Also known as
- Code names: HTI-1088, SHR-1316